The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Open accessAbstract
An emerging approach for treating cancer involves programming patient-derived T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can combat tumour cells once they are reinfused. Although trials of this therapy have produced impressive results, the in vitro methods they require to generate large numbers of tumour-specific T cells are too elaborate for widespread application to treat cancer patients. Here, we describe a method to quickly program circulating T cells with tumour-recognizing capabilities, thus avoiding these complications. Specifically, we demonstrate that DNA-carrying nanoparticles can efficiently introduce leukaemia-targeting CAR genes into T-cell nuclei, thereby bringing about long-term disease remission. These polymer nanoparticles are easy to manufacture in a stable form, which simplifies storage and reduces cost. Our technology may therefore provide a practical, broadly applicable treatment that can generate anti-tumour immunity ‘on demand’ for oncologists in a variety of settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
Monjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics, Z., & Hudecek, M. (2017) · Leukemia · doi:10.1038/leu.2016.180 · Cited by 258
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3185 · Cited by 250
Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in Vivo
Mangraviti, A., Tzeng, S. Y., Kozielski, K. L., Wang, Y., Jin, Y., Gullotti, D., Pedone, M., Buaron, N., Liu, A., Wilson, D. R., et al. (2015) · ACS Nano · doi:10.1021/nn504905q · Cited by 249
CAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 227
Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W. R., Miermont, A. M., Teper, Y., Rudloff, U., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.209 · Cited by 191
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 185
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Gade, T. P. F., Hassen, W., Santos, E. B., Gunset, G., Saudemont, A., Gong, M., Brentjens, R. J., Zhong, X.-S., Stephan, M. T., Stefanski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0436 · Cited by 117
Self-citationEllmeier, W., Sunshine, M. J., Losos, K., Hatam, F., & Littman, D. R. (1997) · Immunity · doi:10.1016/s1074-7613(00)80375-1 · Cited by 115
The Expression of Exogenous Genes in Macrophages: Obstacles and Opportunities
Zhang, X., Edwards, J. P., & Mosser, D. M. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-396-7_9 · Cited by 106
Minicircle DNA vectors for gene therapy: advances and applications
Gaspar, V. M., de Melo‐Diogo, D., Costa, E. C., Moreira, A. F., Queiroz, J. A., Pichon, C., Correia, I. J., & de Sousa, F. P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.996544 · Cited by 104
Dobrenkov, K., Olszewska, M., Likar, Y., Shenker, L., Gunset, G., Cai, S., Pillarsetty, N., Hricak, H., Sadelain, M., & Ponomarev, V. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047324 · Cited by 92
An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity
Fischer, K., Andreesen, R., & Mackensen, A. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00507-5 · Cited by 76
Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor
Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M., & Rivière, I. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000072 · Cited by 70
Marodon, G., Mouly, E., Blair, E. J., et al. (2003) · Blood · doi:10.1182/blood-2002-02-0578 · Cited by 69
Kim, J., Yechan, K., Tzeng, S. Y., & Green, J. J. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.05.040 · Cited by 69
Li, X., Tzeng, S. Y., Liu, X., Tammia, M., Cheng, Y., Rolfe, A., Sun, D., Zhang, N., Green, J. J., Wen, X., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.037 · Cited by 52
A Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon
Burnight, E. R., Staber, J. M. R., Korsakov, P., Li, X., Brett, B. T., Scheetz, T. E., Craig, N. L., & McCray, P. B. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.12 · Cited by 50
Narayanan, K., Yen, S. K., Dou, Q., Padmanabhan, P., Sudhaharan, T., Ahmed, S., Ying, J. Y., & Selvan, S. T. (2013) · Scientific Reports · doi:10.1038/srep02184 · Cited by 49
Magnani, C. F., Turazzi, N., Benedicenti, F., Calabria, A., Tenderini, E., Tettamanti, S., Attianese, G. M. P. G., Cooper, L. J. N., Aiuti, A., Montini, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9955 · Cited by 49
Synthetic biology approaches to engineer T cells
Wu, C., Rupp, L. J., Roybal, K. T., & Lim, W. A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.015 · Cited by 35
Evaluation of Long-term Transgene Expression in piggyBac-Modified Human T Lymphocytes
Nakazawa, Y., Saha, S., Galvan, D. L., Huye, L. E., Rollins, L. A., Rooney, C. M., & Wilson, M. H. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182791234 · Cited by 28
Gene Therapy: The View from NCATS
Brooks, P. J., Yang, N. N., & Austin, C. P. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.29018.pjb · Cited by 16
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Metadata
- Authors
- Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T.
- Venue
- Nature Nanotechnology
- Published
- 2017-04-17
- Volume
- 12
- Issue
- 8
- Pages
- 813-820
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2607356458
- Cited by
- 785
- References
- 31
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.